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Letters to the Editor 
RISPERIDONE INDUCED DYSTONIC 
REACTION AND AKATHISIA 
Sir, 
Risperidone is an atypical antipsychotic 
with a reported lower potential for extrapyrami-
dal side effects at therapeutic doses than 
haloperidol (Marder & Meibach, 1994). Till date, 
there are only case reports of dystonic reaction 
(Faulk et al., 1996) and akathisia (Rosebush et 
al., 1997) during risperidone treatment. This is 
case report of acute dystonic reaction and 
akathisia in a chronic schizophrenic patient dur-
ing initiation with risperidone treatment. 
Mr. B was a 18 year old male with 
DSM - IV diagnosis of chronic schizophrenia in 
acute exacerbation. He was not on treatment 
with any antipsychotic at the time of consulta-
tion. After admission and consent for treatment 
his regimen began with risperidone 1 mg b.i.d. 
on the first day and was increased to 2 mg b.i.d. 
on the second day and to 3 mg bid. on the 
third day. On the fifth day, Mr. B developed acute 
dystonic reaction (torticollis). His only concomi-
tant medication was alprazolam 0.25 mg 
t.i.d. Fifteen minutes after an injection of 
promethazine, 25 mg IV, the attack of dystonic 
reaction was resolved. Since he continued to 
develop intermittent dystonic reaction of the 
same nature he was started on an oral dose of 
trihexyphenydyl 2 mg at morning and afternoon 
and was instructed to continue risperidone and 
alprazolam. He had no recurrence of dystonic 
reaction, however, on the seventh day he started 
complaining of severe restlessness with 
objective evidence of akathisia. For the disa-
bling akathisia he was started on propranolol, 
20 mg t.i.d. which was increased to 40 mg, t.i.d. 
on the tenth day. Even after fifteen days of 
treatment with the above regimen there was no 
improvement for akathisia and the condition of 
the patient deteriorated, hence risperidone was 
discontinued. After a period of one week 
akathisia was completely subsided and he was 
started on a regimen of clozapine which was 
increased to a maximum dose 200 mg. per day 
over a period of one month. Follow up evalua-
tion revealed no dystonia or akathisia but good 
clinical improvement. 
Acute dystonic reaction and other 
extrapyramidal side effects have long been 
associated with D2 receptor blockade of classi-
cal antipsychotics. However, for drugs like 
risperidone it has been proposed -that release 
of D2 receptor blockade at nigrostriatal level by 
the blockade of 5HT2 receptors will lead to lower 
incidence of EPS (Kapur and Remington, 1996). 
Pre clinical pharmacological tests which 
provides the most homologous model of EPS 
in non human primates has shown that both in 
haloperidol sensitised and drug naive monkeys 
risperidone produces considerable dystonic 
reaction at predicted antipsychotic doses 
(Goldstein and Snyder, 1995). This case report 
suggest that close patient monitoring is 
essential concerning the risk of extrapyramidal 
symptoms even for atypical antipsychotics like 
risperidone as it may adversely affect compli-
ance. Being a newer antipsychotic risperidone 
needs further clinical experience to determine 
the comparative risk of extra pyramidal symp-
toms as opposed to typical antipsychotics. 
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EXFOLIATIVE DERMATITIS DUE TO 
CARBAMAZEPINE 
Sir, 
A 57 years, male patients, frequently 
treated with antipsychotics in past for manic epi-
sodes, was kept on carbamazepine mainte-
nance therapy 600 mg per day since three 
months. Relatives called for emergency home 
visit with complaints of restlessness. Not sleep-
ing since three days, itching all over body and 
breathlessness. 
On examination there was pilling of skin 
all over body, multiple bruises and scratches, 
oedema feet-pitting on pressure, legs like el-
ephants, patient was grasping for air and shout-
ing for distress, enable to seat for a few min-
utes, had multiple ronchi and rales on respira-
tory auscultation. 
Patient was immediately hospitalized, 
physician and dermatologist were called. 
Other systemic examinations and inves-
tigations were inconclusive include Hb, TLC, 
DLC, Platelet count, Blood Urea, USG Abdo-
men, X-Ray Chest, fundus. 
Provisionally diagnosed as a case of Exfoliative 
dermatitis 
- Carbamazepine was stopped 
- Haloperidol 20 mg and lorazepam 10 mg per 
day titrated 
- Dexamethasone 24 mg per day intravenously 
given, rapidly tapered and omitted in seven 
days 
- Anti allergic, anti-histaminics hydroxyzine 
(Atarax) 75 mg per day was given. Gradually 
tapered in two months 
- Broncho dilators and other symptomatic drugs 
were given 
- Patient was discharged after seven days and 
was itch free after two months 
- Comments: we must be open to accept, diag-
nose, manage side effects of drugs 
-Liaison with other speciality is very rewarding 
-Uncommon side effects may be less commonly 
diagnosed 
- In inter episodic periods of bipolar affective 
disorder psychotherapeutic management may 
be tried, instead of mood stabilizers for years. 
KANABAR JAYESH, M.D. (Psychiatry) Canal Road, Near 
Nagarik Bank, Rajkot 360 002, Gujarat 
PREVALENCE OF MENTAL AND 
BEHAVIOURAL DISORDERS IN INDIA : A 
META-ANALYSIS 
Sir, 
Estimation of the magnitude of psychiat-
ric and behavioural disorders is essential for 
planning the implementation of National Men-
tal Health Programme in India. Lack of a com-
prehensive nationwide data on these problems 
have led to a long felt need for a metaanalysis 
on the magnitude of these problems in the sub-
continent. The present article by Reddy and 
Chandrasekhar (1998) has fulfilled this lacunae. 
Metaanalysis gives the summary of several 
studies having similarity in terms of selected 
methodological and analytical criteria (Cook et 
al., 1995). However, the problem of potential 
bias in such type of study should be kept in mind 
before accepting the final results. 
The studies selected for the meta -analy-
sis had the inclusion criteria of a house to house 
survey. In absence of properly selected study 
population based on scientifically valid sampling 
techniques as reported in few of the selected 
studies (Elnagar et al., 1971; Nandi et al., 1975; 
Nandi et al., 1977; Nandi et al., 1980a; Nandi et 
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